Cornea

Christine Sindt, OD, FAAO, Clinical Professor of Ophthalmology and Visual Sciences at the University of Iowa School of Medicine, talked about her session at the meeting focusing on higher order aberrations and the correction of complicated optics on scleral contact lenses.

Alan Glazier, OD, FAAO, talked about a session he is a moderator in that discusses the education of the public on keratoconus, from screening to diagnosis, and the roles clinicians can take to assist in the anxieties of the patients.

Andrew Morgenstern, OD, FAAO, FNAP, President and Co-founder of IKA, talked about his session at the meeting centering around the pediatric prevalence of keratoconus.

Alternate methods of screening may lead to earlier diagnosis of disease.

A team of Chinese researchers have been working on a way to continuously and more comfortably detect these tiny fluctuations in pressure, such as contact lenses that transmit signals to receptor glasses.

A singular celebration of science over the decades

Elias Kahan, MD, speaks about wide-field contact specular microscopy and the expanding scope of corneal endothelial research.

The 18th annual Controversies in Modern Eye Care conference, held on May 4, 2024, in Los Angeles, was co-chaired by Neda Shamie, MD, and Arjan Hura, MD, with the aim of discussing the latest advancements in eye care.

Hura highlighted some of the key takeaways from the Controversies in Modern Eye Care symposium where presenters and attendees shared their insights into the latest advancements in refractive surgery, retina care, and collaborative eye care.

The trial is evaluating AURN001, a combination cell therapy product comprised of neltependocel (allogeneic human corneal endothelial cells [CECs]) and Y-27632 for the treatment of corneal edema secondary to corneal endothelial dysfunction.

Joseph Izatt was a skilled researcher and inventor who played a foundational role in the development of optical coherence tomography.

According to the company, the feedback from the interactive meetings will provide guidance for the path to a PMA submission.

At this year's ASCRS meeting in Boston, Massachusetts, Ophthalmology Times Europe caught up with Eris Jordan, OD talked about the big plans the Boston-based startup has for the year ahead. Watch the full video to find out what's in store for the company and its novel cell therapy in Japan, Canada and the United States in 2024.

Neda Nikpoor, MD, shares highlights from her presentation on the Light Adjustable Lens during an ASCRS symposia on IOL calculations.

Pterygium is an ocular disease commonly referred to as “surfer’s eye,” which can result from exposure to high levels of UV radiation.

Rahul S Tonk, MD, MBA, sat down to discuss a roundtable discussion he had on DMEK and DSEK surgery at this year's ASCRS meeting held in Boston, Massachusetts, from Friday, April 5, to Monday, April 8, 2024.

Results of the study indicated that systemic treatment led to elevations in liver function test results, with some patients experiencing values twice as high as normal.

Researchers conducted a retrospective chart review spanning from January 2015 to January 2021 to compare the incidence rates of infectious keratitis before and during the pandemic among PRK patients.

Ula Jurkunas, MD, sat down to discuss her presentation on the management of anterior corneal disease at this year's ASCRS meeting held in Boston, Massachusetts.

The company announced it will share clinical data at Eyecelerator and the American Society of Cataract and Refractive Surgery 2024 Annual Meeting in Boston.

The 1-time, intracameral injection is a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.

Alice Epitropoulos, MD, discusses the importance of considering ocular surface health in cataract surgery patients.

Alexander Movshovich, MD, PhD, a specialist in keratopigmentation, sat down to talk about the controversy surrounding the procedure after it went viral on social media.

Early keratoconus screening advocated

Shifting the treatment paradigm can lead to less pain and inflammation.

The funding has been awarded to BIENCO, which is working to cure one of the most common causes of blindness in the world by developing cost effective, individually tailored, superior corneas.

OK-101 is the first IND clearance granted by the FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain.

Patient selection is important.